BofA analyst Jason Gerberry raised the firm’s price target on ProKidney (PROK) to $4 from $3 and keeps a Neutral rating on the shares. The analyst cites the company’s data that shows better prospects for its cell therapy drug REACT, noting that while the recent data from Novo’s (NVO) semaglutide FLOW study showed that its drug has limited use for patients with stage 3b-4 CKD patients, this is the market that ProKidney’s REACT is expected to be used in.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
- ProKidney sees cash runway into 4Q25
- ProKidney reports Q1 EPS (16c) vs. (16c) last year
- ProKidney Reports Business Updates and First Quarter 2024 Financial Results
Questions or Comments about the article? Write to editor@tipranks.com